Potential biomarkers for hepatoblastoma: Results from the SIOPEL-3 study

21Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Hepatoblastoma (HB) is a rare malignant liver tumour found in infants. Many heterogenous histological tumour subtypes exist. Although survival rates have improved dramatically in recent years with the use of platinum-based chemotherapy, there still exists a subset of HB that does not respond to treatment. There are currently no tumour biomarkers in use and in this study we aim to evaluate potential biomarkers to aid identification of relapse cases that would otherwise be overlooked by current prognostication. This may identify patients that would benefit from more aggressive therapy and could improve overall survival rates. We used immunohistochemistry to analyse the expression of β-catenin, E-cadherin, Cyclin D1, Ki-67 and alpha-fetoprotein (AFP) protein in tumours from 91 patients prospectively enroled into the SIOPEL 3 clinical trial. The relationship between these biomarkers and clinicopathologic features and patient survival were statistically analysed. We identified one biomarker, Cyclin D1, which has a correlation with mixed epithelial/mesenchymal HB approaching significance (P = 0.07). Survival analysis using these markers has revealed two potential prognostic indicators; Cyclin D1 and Ki-67 (P = 0.01, 0.01). © 2012 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Purcell, R., Childs, M., Maibach, R., Miles, C., Turner, C., Zimmermann, A., … Sullivan, M. (2012). Potential biomarkers for hepatoblastoma: Results from the SIOPEL-3 study. European Journal of Cancer, 48(12), 1853–1859. https://doi.org/10.1016/j.ejca.2011.10.019

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free